Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection

Inclusion Criteria:

* Patients with a first diagnosis of HCC who have undergone a curative resection
* Radiologic evidence of disease free ≥4 weeks after complete surgical resection
* Full recovery from surgical resection or post-operative transarterial chemoembolization before randomization
* Randomization needs to occur within 12 weeks of the date of surgical resection
* High risk for HCC recurrence as protocol defined
* Child-Pugh Score, Class A
* ECOG performance status 0 or 1
* No prior systemic anticancer therapy for HCC
* Adequate hematologic and organ function

Exclusion Criteria:

* Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
* Evidence of residual, recurrent, or metastatic disease at randomization
* History of hepatic encephalopathy or organ transplantation
* Patients who are in the waiting list for liver transplantation
* Patients with Vp4 portal vein thrombosis
* Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or other immunotherapy
* Pregnant or lactating women